Currently, pharmacogenetic studies are at an impasse as the low prevalence (<2%) of most variants hinder their pharmacogenetic analysis, with population sizes often inadequate for sufficiently powered studies. Grouping rare mutations by functional phenotype rather than mutation site, can potentially increase sample size. Using human population based studies (n=1,761) to search for dysfunctional human prostacyclin receptor (hIP) variants, we recently discovered 18 non-synonymous mutations all with frequencies less than 2% in our study cohort. Eight of the 18 had defects in binding, activation, and/or protein stability/folding. Mutations (M113T, L104R, R279C) in three highly conserved positions demonstrated severe misfolding, manifested by impaired binding and activation of cell surface receptors. To assess for association with coronary artery disease, we performed a casecontrol study, comparing coronary angiographic results from patients with reduced cAMP production arising from the non-synonymous mutations (n=23) with patients with non-synonymous mutations that had no reduction in cAMP (n=17). Major coronary artery obstruction was significantly increased in the dysfunctional mutation group in comparison to the silent mutations. We then compared the 23 dysfunctional receptor patients to 69 age and risk-factor-matched controls (1:3). This verified the significantly increased coronary disease in the nonsynonymous dysfunctional variant cohort. This manuscript demonstrates the potential utility of in vitro functional characterization in predicting clinical phenotypes, and represents the most comprehensive characterization of human prostacyclin receptor genetic variants to-date.
INTRODUCTION
Single nucleotide polymorphisms (SNPs) occurring in DNA coding regions are sequence changes that result in either synonymous (i.e. no change in amino acid sequence) or nonsynonymous (change in amino acid sequence) mutations. They are implicated in the pathogenesis of diseases (1) , in addition to the efficacy of drugs, and in drug-to-drug interactions (2) (3) (4) . It is now generally believed that greater than 80% of the observed variability between individuals are the result of genetic variants (5) . Numerous databases including the National Center for Biotechnology Information (NCBI dbSNP) have accumulated millions of SNPs, and a growing list of clinical trials seek to address the role of SNPs in pathophysiology and treatment response (6) (7) (8) .
Utility of prostacyclin receptor biochemical analysis
Despite the rapid accumulation of data, surprisingly little has entered clinical practice. This may be in part due to the requirement for very large cohorts in order to perform an adequately powered study for the rarer mutations. Detailed genetic variant functional analysis in biochemical systems may provide a possible solution.
The human prostacyclin receptor gene (PTGIR) spans approximately 7,000 bases along chromosome 19 (locus 19q13.3) and is comprised of 3 exons separated by two introns: one intron lies upstream from the ATG start codon and the other at the end of the sixth transmembrane helix (9) . The human prostacyclin receptor protein (hIP), composed of 386 amino acids, has a molecular mass of 37-41 kDa, depending upon its glycosylation state (10) . Expression of hIP is distributed throughout the body, with predominate cardiovascular expression on platelets and VSMCs, and is commonly associated with coupling to the G αs subunit of the heterotrimeric G-protein.
Upon receptor activation, G αs stimulates membrane-bound adenylyl cyclase (AC) to catalyze formation of the second messenger, cAMP (11) , (12) . In the context of platelet function, this second messenger cascade leads to platelet inactivation and is a critical component of thrombogenic homeostasis. Based upon sequence homology, ligand structure, and overall receptor functionality, hIP is classified as a Class A rhodopsin-like G-protein coupled receptor (GPCR). We have previously identified the putative agonist binding pocket of the hIP receptor, comprised of four amino acids residues critical for receptor-ligand recognition. Furthermore, defined residues within the TM domain demarcate the potential molecular path by which the ligand binding-induced signal is transduced through the receptor protein to cytoplasmic effector molecules (13, 14) .
Several lines of investigation have suggested that dysfunctional hIP mutations may have critical physiological consequences. Studies of prostacyclin receptor (IP) knockout (IP -/-) mice have shown increased propensities towards thrombosis (15) , intimal hyperplasia and restenosis (16) , and reperfusion injury (17) . More recently, prostacyclin receptor activity has been shown to have an atheroprotective effect in pre-menopausal knockout (IP -/-) female mice (18) . Such in vivo findings implicate dysfunctional IP activity in cardiovascular disorders, including stroke, myocardial infarction, and hypertension. Of note has been the world-wide withdrawal of the selective COX-2 inhibitors rofecoxib (Vioxx) and valdecoxib (Bextra), whose discriminating suppression of COX-2-derived prostacyclin (PGI 2 ) and its hIP-mediated cardioprotective effects led to increased risk of cardiovascular events (e.g., myocardial infarction and thrombotic stroke), particularly in predisposed patients (19) .
Our recent discovery and characterization of the first known naturally-occurring hIP variants (20) provides further insight into the molecular mechanism and cardioprotective function of this receptor. Since these initial observations, there has only been one similar publication describing 2 additional genetic variants in the coding region of PTGIR within a Japanese cohort (21) . We recently initiated a large scale sequencing study to discover novel prostacyclin receptor genetic variants (22, 23) . Here we report complete characterization of 18 rare non-synonymous mutations in a COS-1 overexpression system. Eight of these mutants exhibit deficiencies, providing insights into critical regions of receptor structure/function. Additionally, to demonstrate the utility of such characterization, we performed a case controlled study focusing on disease severity in those patients for which we had coronary angiography results. Such insights may prove critical in the development and design of prostacyclin based therapies targeted against cardiovascular disease.
Utility of prostacyclin receptor biochemical analysis oligonucleotide primers (Sigma-Genosys ---The Woodlands, TX) in both the sense and the antisense direction extending 10 to 12 nucleotides 3' and 5' from the targeted mutation site were used, along with Pfu buffer, dNTPs and Pfu DNA polymerase (Stratagene ---Austin TX). PCR mutagenesis was performed, initially denaturing at 96 o C for 5 minutes, followed by 32 cycles of 96 o C for 1 minute, annealing at 55 o C for 1 minute, and polymerization at 68 o C for 12 minutes. PCR products were treated with Dpn1 restriction enzyme (Promega ---Madison WI) to digest wild type parent DNA.
Competent DH5α E. coli cells (~2 x 10 9 cells) (Invitrogen ---Carlsbad, CA) were transformed with the PCR mutagenesis product and plasmid DNA was extracted from ampicillin resistant colonies (Qiagen mini-prep DNA isolation kit) and sequenced (Molecular Core Facility, Dartmouth Medical School, Hanover, NH).
Transformation of COS-1 Cells and membrane preparation
Transfection of COS-1 cells using Diethylaminoethyl-Dextran (DEAE-Dextran; Sigma ---St. Louis, MO) has been previously described (25) : Cells were plated on 15 cm plates and incubated at 37 o C in 5% CO 2 atmosphere to approximately 60% confluence. Cells were transfected with mutant or wild type cDNA (20 ųg/plate). Following incubation for 48 hours, membrane preparations were made from the transfected COS-1 cells using differential centrifugation (14) . 50 (mean ± SE) determined for wild-type hIP1D4 and mutant constructs.
Competition and saturation binding studies

Confocal Immunofluorescence Microscopy
COS-1 cells were seeded into six-well tissue culture plates containing sterilized Poly-L-Lysine (Sigma) treated glass cover slips, and transfected with 1.0g/ml of wild-type or mutant hIP DNA. Cells were fixed and permeabilized 48 hours posttransfection in ice-cold methanol. Prostacyclin receptors were labeled using Anti-1D4 monoclonal antibody (C-terminal tagged hIP), followed by goat anti-mouse IgG F(ab') 2 AlexaFluor  568 fluorescent antibody (Molecular Probes, Inc.). The endoplasmic reticulum was labeled using Anti-Calnexin polyclonal antibody (Stressgen Bioreagents), followed by goat antirabbit IgG AlexaFluor  488 fluorescent antibody (Molecular Probes, Inc.). Cells were post fixed with 4% paraformaldehyde (Fluka) 5 min., mounted with ProLong Gold with DAPI and examined via confocal microscopy, using a Zeiss LSM 510 Meta Laser Scanning Confocal Microscope System (i.e., inverted Zeiss Axiovert Utility of prostacyclin receptor biochemical analysis 200 microscope with two conventional photomultipliers and one meta polychromatic multi-channel detector) (Carl Zeiss Microimaging, Inc. ---Thornwood, NY). Representative cells were selected and images captured at highresolution (63x), for cytoplasmic or plasma membrane localization.
Molecular modeling of hIP receptor
Binding, activation, and expression analysis are interpreted in the context of computer modeling (based upon our current model of hIP) to rationalize structural reasons for observed defects. To assist with interpretation of structural interactions altered by non-synonymous variants, we developed a theoretical three-dimensional homology model of the seven transmembrane -helices of the hIP receptor, using the internetbased protein-modeling server, SWISS-MODEL (GlaxoSmithKline ---Geneva, Switzerland) (26) . The homology model was generated, using the 2.8Å-resolution X-ray crystallographic structure of the bovine rhodopsin receptor as the template (1HZX). The transmembrane domains were energy minimized, utilizing the Gromos96 force field to improve the stereochemistry of the model and remove unfavorable clashes (SWISS-MODEL). Extracellular loops were constructed based on Jpred consensus predictions. The constructed loops were minimized and attached to the modeled transmembrane domains. Although our model is a useful first pass tool in providing preliminary insights and predictions of hIP structure function, biochemical and molecular pharmacological techniques are necessary to confirm our hypotheses. Structural predictions are thus based upon analysis of the naturally occurring mutations with further assessments based upon integrated predictions between mutations, ligand binding, receptor activation, and molecular modeling studies.
Nested case-control study For most of the patients, coronary angiography results were available to assess severity of any coronary artery blockages. There are three main coronary arteries that supply the heart and thus significant blockages in each (greater than or equal to 50% diameter narrowing) are deemed clinically significant. Thus they are classified from zero (normal clean vessels) to 3 (significant blockage of all three vessels), 3 being the most severe form of coronary artery disease. We had coronary angiographic results for 40 patients with nonsynonomous hIP variants (6 x V15A, 1 x V25M, 1 x L104R, 1 x G181A, 20 x R212C, 2 x R215C, 7 x P226T and 2 x S319W). All patients were heterozygotes except one R212C patient who was homozygous for the mutation. The remaining characterized mutants were identified in "healthy volunteers" below the normal age of onset of cardiovascular disease symptoms (e.g. M113T was found in a 27 year old Mexican male, R279C in a 47 year old Mexican male, the R77C in a 18 year old Chinese female, R212H in a 22 year old Chinese male, and I293N in a 24 year old Chinese male). As such, there was no angiographic data for these individuals.
Whether these individuals might go on to develop cardiovascular disease with increasing age remains to be determined. For those whom we had complete angiographic results as the numbers were small we divided them into those with functionally defective mutations (23 patients with reduction in cAMP production; 20 x R212C, 2 x R215C, 1 x L104R) and variants with no significant reduction in cAMP (17 patients; 6 x V15A, 1 x V25M, 7 x P226T, 2 x S319W and 1 x G181A). Results in each group were pooled and initially analyzed using Student t-tests. There was no significant difference in age between the two groups. We then assessed separately for association with disease followed by association with disease severity.
A second case control study was performed using a newly established database of 5,560 coronary angiograms. Controls were selected to match the 23 cases (3:1 ratio; 69:23) for sex, age, body mass index and risk factors including hypertension, diabetes, hyperlipidemia, and smoking. Controls were the best matches that had the minimum risk factors to that of each case, and thus overall the controls had more risk factors than the cases. Number of significant occlusions (>50%) of the three major arteries (LAD, LCX and RCA) were compared for both groups.
Statistical analysis
For the in vitro testing and the nested case-control study, analysis of variance (multiple comparison post-hoc test, Newman-Keuls) delineated statistically significant differences (p<0.05) Utility of prostacyclin receptor biochemical analysis between multiple groups, or an unpaired Student's t-test for direct comparison between two groups. All experiments were repeated at least 3 times (in duplicate) with an internal wild-type control. For the analysis of disease association Chi-square test was initially used to determine an Odd Ratio (OR) and 95% confidence limits. Vessel involvement was compared between cases and matched controls and reported here using the likelihood ratio statistic from conditional logistic regression. In addition we compared the data using generalized estimating equations specifying cases and their matched controls as clusters, as well as paired t-tests of the difference between cases and the average of their matched controls. All of these approaches yielded very similar results. Statistical significance was determined to be a p-value <0.05.
RESULTS
We have thus far detected 18 rare (<2% prevalence) non-synonomous mutations in the coding region of the human prostacyclin receptor gene, upon sequencing 1,761 human subjects ( Fig.  1) . Our initial goal for the current study was to analyze receptor variants for ligand binding (K D ) and activation (cAMP EC 50 ) in parallel, using an in vitro COS-1 overexpression system previously used to successfully characterize 5 mutations (V25M, R77C, R212C, R212H and R279C) (20, 23, 27, 28) . We now report the characterization of the 13 newly identified non-synonymous mutations, including two variants (L104R and M113T) at highly conserved positions (100%) across all prostanoid receptors. Such conserved residues, in addition to residues unique to the hIP, provide insights into critical structural requirements for hIP and prostanoid receptor function. This is particularly important clinically as prostacyclin dysfunction (reduced prostacyclin production or a defective receptor) has recently been shown to lead to acceleration of cardiovascular disease.
Mutations at highly conserved sites (L104R, M113T, R279C)
Positions L104 (TMIII), M113 (TMIII), and R279 (TMVII) are 100% conserved across all prostanoid receptors suggesting that these positions are critical for both hIP and prostanoid receptor structure and function. It was therefore not surprising that alterations at each of these positions produced severe defects, particularly in ligand binding, as well as in activation and protein expression ( Table 1) . We have previously demonstrated that R279 is an important counterion for the C1 carboxylate residue of prostacyclin (29) and that a SNP with a cysteine in this position has deleterious effects on binding and activation (22) . The novel L104R and M113T mutations, located in transmembrane helix three, each exhibited a lack of specific counts upon competition binding ( Table 1) indicating severely compromised ligand binding. Western analysis (Fig. 2) on membrane preparations showed abundant protein relative to wild-type hIP expressed in COS-1 cells; however, saturation binding on the same preparations showed reduced ligand recognition suggestive of protein misfolding. Confocal microscopy analysis confirmed significant endoplasmic reticulum retention and decreased cell surface expression (Fig. 2) particularly for the M113T. Activation analysis, using cAMP detection, was consistent with the reduced binding and misfolding. This was particularly notable in M113T, where increasing concentrations of iloprost failed to increase cAMP signaling above background ( Fig.  3 and Table 1 ).
Molecular modeling revealed probable defects in receptor structure. The completely conserved leucine at position 104 in TMIII may play a critical role in inter-helical interactions between TMIII and TMIV (Fig. 4A) . The completely conserved methionine at position 113 in TMIII, when changed to Thr appears to generate a possible steric hindrance with TMVI (Fig 4B) . Thus, two completely conserved residues, leucine 104 and methionine 113, likely serve critical roles mediating inter-helical interactions between transmembrane domains three and six, the disruption of which leads to severe protein misfolding. Of note, movement of TMIII and TMVI are critical in the activation of rhodopsin and probably G-protein coupled receptors in general (30) . It should be emphasized that our observations are based upon the best homology model we have available to date and not a structure, and as such the accuracy remains questionable until more definitive structural data Utility of prostacyclin receptor biochemical analysis becomes available (e.g. through crystallography or NMR).
Lessons from other functionally defective polymorphisms (R77C, R212C, R212H, R215C, I293N)
Of the remaining functionally defective mutations, the 293 position (cytoplasmic end of TMVII) is conserved among 69% of all prostanoid receptors. There were clear defects in binding and expression, with additional increases in EC 50 , although not statistically significant ( Table 1) . cAMP production was clearly reduced in comparison to wild type levels (Fig 3B) . The isoleucine at position 293 at the interface of TMVII and the C-terminal tail may interact with Pro289 in TMVII (Fig. 4) . Pro289 is a highly conserved residue (98% conservation) found within TMVII and part of the important highly conserved NPXXY motif (in the case of the hIP (DPXXF) motif (14) .
Both R77C and R215C exhibited reduced cell surface expression upon saturation binding (0.3 ± 0.04 pmol/mg membrane protein, n=3 p<0.01 and 0.3 ± 0.05 pmol/mg membrane protein, n=6, p<0.01 respectively). Both demonstrate reduced cAMP production at physiologically relevant concentrations of agonist (Fig 3B) . The remaining two mutations (R212C and R212H) which have been included to complete the set of 18, have previously been characterized (20, 27, 31) and exhibit clear activation defects (Table 1, Fig. 3) The functionally silent polymorphisms Of the 18 non-synonymous mutations, ten of them exhibit no significant activation or expression problems ( Table 1) . We were somewhat surprised at this number despite some dramatic physicochemical amino acid changes. The G231R and P226T variants are both located in the critical third intracellular loop (known interaction site with heterotrimeric G-protein), while S319W, E354D and S369R are located in the C-terminal tail. It is possible that these silent amino acid changes are accommodated in the hIP structure. However, because we analyzed the mutations in a non-native overexpression system, we cannot rule out that these mutations may have defects in other pathways (particularly hIP transport) that may be of clinical importance to other disease processes (e.g. asthma or bleeding). (32) . In human patient blood we were able to detect basal levels of 0.018 ± 0.001 nM (n=8, cardiology patients). Local concentrations in regions of stimulated prostacyclin release are likely to be considerably higher, in the range of the observed EC 50 (5nM) determined using agonist on human coronary vascular smooth muscle cells (Fig 5A) . This result is consistent with the EC 50 and binding affinities (nM range) for hIP expressed in COS-1 (Fig 3 and  Table 1 ). Detailed full dose-response curves for the 8 dysfunctional mutations are therefore provided in Fig. 3A and 3B . Reduced cAMP production was prominent at physiological agonist concentrations (shaded box) for L104R, M113T, R212H, R212C and R279C (Fig. 3A) all of which had abnormal EC 50 . For the mutations R77C, R215C and I293N who had normal EC 50 (Table 1) there were also clear defects in cAMP production at the physiological range ( Figure. 3B) .
Production of cAMP at physiological agonist concentration; the importance of full dose response analysis
From the modeling and secondary structure, individual mutations can lead to quite different structural perturbations, however we believe that the resultant signaling defect is of greatest importance for association with clinical disease. It was therefore mandatory to initially estimate physiological concentrations of agonist in order to determine whether there is a reduction in hIPstimulated cAMP production at those concentrations in human coronary vascular smooth muscle cells. As the half life of prostacyclin is very short (seconds to minutes) we used an ELISA assay for the stable metabolic product of prostacyclin, 6-keto-PGF1(Cayman Chemical, Ann Arbor, MI)
Prostacyclin receptor function in coronary vascular smooth muscle cells
We then proceeded to assess the functional importance of prostacyclin receptor activation by nM concentrations of agonist in both coronary vascular smooth muscle cell proliferation and differentiation, as these functional characteristics are important in retarding the formation of an atherosclerotic plaque occlusion. The iloprost dose-response for cAMP production in primary Utility of prostacyclin receptor biochemical analysis human coronary VSMC showed an EC 50 of 5.5 ± 2.5 nM (mean ± standard error, n=4) (Fig 5A) . Iloprost inhibited the serum-induced proliferation of human coronary VSMC in a dose-dependent manner (1nM and 100nM, all p<0.001 versus 15% FBS positive control, Student t-test) (Fig. 5B) . Iloprost also induced a dose-dependent increase in the SM2 isoform of smooth muscle myosin heavy chain (SM-MHC) and calponin, recognized markers of smooth muscle cell differentiation (33) (Fig. 6) . Reduced hIP signaling would therefore lead to hyper-proliferation and de-differentiation; hallmarks of atherosclerosis and coronary vessel occlusion. Thus normal signaling (via cAMP) at nM concentrations of hIP agonist, plays an important cardioprotective role.
Variant association with disease may be grouped by downstream signaling rather than the position of the variant.
Although COS-1 analyses have provided important insight into the structure-function relationship of the prostacyclin receptor, we must also assess whether such studies can offer useful information/correlation to clinical disease. This is particularly relevant in light of our data demonstrating the role of prostacyclin in coronary VSMC proliferation and differentiation. As most of our samples were obtained from a high risk cardiology cohort, many of our patients had coronary angiograms available for analysis. Coronary angiograms are currently the gold standard in determining the presence or absence of coronary artery disease. In a case-control study, we initially directly compared patients with silent non-synonymous mutations (no biochemical defect cohort, controls n=17) with those with detected biochemical defects upon COS-1 analysis (cases -defect, n=23). There was no significant age difference between the two groups (controls = 57.0 ± 3.1 yrs, cases = 63.3 ± 2.5 yrs, p=0.12) (Fig. 7A) . The BMI for the cases were 28.3 ±1.7 and the controls 32.1 ± 1.8 (p=0.15). The cardiovascular risk factors for the cases (n=23) versus controls (n=17) were male (74% cases vs 71% controls), hypertension (74% cases vs 60% controls), hyperlipidemia (70% cases vs 65% controls), diabetes (27% cases vs 29% controls), family history (43% cases vs 35% controls) and smoking (18% cases vs 6% controls). Initial chisquared analysis demonstrated that there was a significant association of the functional defect group (cases) with coronary artery obstruction (OR, 4.67 [0.99 to 22 .02], p=0.04) in comparison to the group with silent mutations. Moreover, upon assessment of disease severity based upon scores from zero (no vessels significantly occluded) to 3 (all 3 major coronary vessels occluded), patients with mutations that demonstrated reduced cAMP had significantly more coronary blockages than those who exhibited normal cAMP production (controls = 1.0 ± 0.26 vessels, cases = 1.7 ± 0.23 vessels, p=0.039) (Fig. 7B) . Although the two groups only represented a small handful of mutations, the potential utility and importance of grouping mutations by in vitro analysis appears promising. Variants may be grouped by downstream signaling rather than the position of the variant.
To further reaffirm our hypothesis that reduced cAMP (from hIP dysfunction) is associated with increased coronary disease and is not due to increased cardiovascular risk factors in the cases, we performed a case:control study (1:3) using age and risk-factor-matched controls from our cardiovascular population. A database was established for 5,560 patient angiogram files and a program written to select controls based upon age, BMI, and other cardiovascular risk factors (i.e., family history, hypertension, hypercholesterolemia, diabetes, and smoking status). As each of the controls had to have at least the same risk factors present in the cases, some of the best matches had other risk factors (most often hypertension and/or hypercholesterolemia) in addition to the risk factors in the case subject. Thus, the overall risk factors were higher in the controls versus the cases (Fig. 8A) . The age and BMI were closely matched in the two groups. Scatter plot analysis demonstrated a significant portion of both control and cases were obese (BMI > 30) (Fig. 8B) . The new control patients were additionally genotyped for the prostacyclin receptor. The sequences demonstrated no nonsynonomous mutations. Upon assessment of number of major vessels occluded, there were significantly more vessels occluded in cases than controls (p=0.022) (Fig. 8C) . Patients who had hIP variants with normal cAMP production and function had occlusive disease in 1.0 ± 0.26 vessels (Fig 7B) in comparison to the 69 control Utility of prostacyclin receptor biochemical analysis patients (1.0 ± 0.11 vessels) (Fig 8C) . This further supports that (in our high cardiovascular risk population) dysfunctional hIP variants are associated with significantly increased coronary artery occlusion and there is a lack of association with increased coronary occlusion in those with nonsynonomous mutations and normal hIP function.
DISCUSSION
Our goal for this study was to demonstrate that detailed biochemical analysis of rare prostacyclin receptor genetic variants may be useful in identifying patients at significant risk of developing serious cardiovascular disease. This is particularly important and timely with recent demonstration of the critical role that hIP plays in development of cardiovascular disease (27, 34, 35) . Characterization of these mutations additionally provides important insights into the amino acid requirements for hIP structure and function, and the importance of complementing basic sciences with clinical studies.
Human prostacyclin receptor non-synonymous polymorphisms
Receptor polymorphisms are emerging as important contributors to the understanding of both disease pathophysiology and therapeutics (36) (37) (38) . The presence of such variants, especially those that alter ligand binding and G-protein coupling, will have important effects in both pathophysiology and response to receptor targeted therapy (39) . Examples of such variants affecting ligand binding include, transmembrane domain variants in rhodopsin (40) , the dopamine D4 receptor (41) and the vasopressin V2 receptor (42) . Intracellular loop variants in the dopamine D2 receptor (43) , the endothelin ETB receptor (44) , and the vasopressin V2 receptor (45) , exhibit impairment in G-protein coupling. We have previously described and characterized singlenucleotide polymorphisms (SNPs) in the hIP (20) . This was followed by extensive sequencing of patient samples to discover novel genetic variants (23) . We now report our most recent finding from sequencing a total of 1761 patient samples, from which we have found 18 mutations that lead to a change in amino acid. It was therefore important to examine these variant receptors for functional abnormalities. The specific functional defect may prove to be more important than the site of mutation on the prostacyclin receptor. These prostacyclin receptor mutations may be analogous to CFTR (chloride channel) mutations leading to cystic fibrosis, and rhodopsin mutations leading to Retinitis Pigmentosa, in that there are now hundreds of rare mutations for which there are insufficient numbers to prove a direct disease association. However, based upon the functional defect observed for the 508 (most common cystic fibrosis genetic defect) and P23H (most common Retinitis Pigmentosa mutation) it has been shown, and generally accepted, that a functional defect leads to disease in these rarer mutations (46) . This highlights the critical importance for the additional study of the receptors themselves and detailed assessment of the signaling pathways. Patients with similarly dysfunctional mutations may ultimately benefit from the same therapies.
New insights into hIP structure and function
We have recently made a number of contributions to current knowledge on the structure and function of the hIP including a putative agonist-binding pocket for the hIP (29) , conformational changes leading to downstream receptor signaling (13, 14) , and dual disulfide bonds in the hIP (47) . Studies using both natural (polymorphisms) and unnatural (site-directed) mutations will provide further critical information on the binding and activation of the hIP. Both the L104R and M113T have identified critical residues required to maintain structural integrity, the replacement of which leads to severe protein misfolding. This knowledge may assist in the rational design of stable, orally bioavailable prostacyclin analogues for combating cardiovascular disease. Indeed the presence of the mutations may require the design of differentlystructured analogues to combat prostacyclin related diseases. Due to the 100% conservation across prostanoid receptors for L104R and M113T, these principles will likely extend to the whole family of prostanoid and prostanoid related G-protein coupled receptors.
A further area that remains unexplored is the detailed analysis of the non-synonymous mutations on agonist dependent internalization and trafficking as has recently been elegantly described (48). Indeed our saturation binding experiments and confocal microscopy suggests that some of these mutations may have defects in such trans-cellular movements. Further detailed studies, particularly under native conditions would be of great importance in correlating in vitro function with clinical disease.
Receptor structure and function under native conditions Although COS-1 detected functional defects are important to finding correlations to clinical disease, there additionally may be mutations that exhibit defects only under conditions of stress. While many genetic variants may be silent under normal physiological conditions, underlying functional abnormalities can manifest only in a diseased state (49, 50) . We have previously determined that an R212H mutation (expressed in COS-1 cells) leads to defective ligand binding and activation, particularly when exposed to stress conditions such as acidosis, e.g., pH 6.8 (20) . During pathological stress such as respiratory or cardiac failure (where severe acidosis may provoke defective prostacyclin binding), the added receptor defect may promote vasoconstriction and/or thrombosis, warranting urgent correction of pH to restore proper receptor function and prevent catastrophic ischemia. Thus, despite the utility of COS-1 analysis, parallel analysis of patient tissues ex vivo may provide additional essential information.
Limitations
In addition to limitations of our in vitro testing and in vivo correlations, as described above, the current study (although based upon the analysis of 1,761 patients) is relatively small, particularly when mutations of such low prevalence are being studied, and many of our mutations are not represented. It is, therefore, mandatory that further confirmation is required on a larger scale. Following our group of patients over many years will provide further information particularly those with the highly conserved mutations and currently no angiographic results.
All patients studied except for one R212C were heterozygote. This strongly supports a dominant negative effect conferred by the mutant receptor probably through a heterodimerization mechanism as recently suggested (51) . With larger clinical studies more dramatic effects conferred by homozygote mutations may be uncovered. Alternatively knock-in mice studies may be informative.
The molecular modeling presented in this manuscript is based upon the crystal structure of rhodopsin, using multiple structural and energyminimization algorithms. While we recognize that it remains a crude model at best, based upon extensive mutagenesis and complimentary predictions, we believe that it is reasonably accurate. Crystallization studies in addition to NMR studies will be the ultimate proof of accuracy. However, although the structural mechanism of specific mutations may be important in designing drugs for therapy, resultant downstream signaling defects is likely the most important for disease correlation.
Conclusions
We report the most comprehensive biochemical study of hIP non-synonymous polymorphisms to date, extending fundamental structure function to clinical observations. This has provided significant insights into critical residues required for hIP and prostanoid receptor structure and function. We have additionally highlighted the importance of biochemical characterization, as only functional defects correlated with the severity of clinical disease as observed through coronary angiography. Such pooling of biochemically characterized variants focusing on functional signaling defects rather than the site of the mutation, may ultimately be useful for correlation of function with clinical disease for rare variants.
Utility of prostacyclin receptor biochemical analysis
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